BRIEF published on 11/27/2024 at 18:05, 1 year 5 months ago ABIVAX: Update of Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights Abivax Financial Transparency
BRIEF published on 11/19/2024 at 22:35, 1 year 5 months ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 1 year 5 months ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 1 year 5 months ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE published on 11/14/2024 at 22:01, 1 year 5 months ago Abivax presents third quarter 2024 key financial information Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
BRIEF published on 11/13/2024 at 22:06, 1 year 5 months ago Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor Biotechnology Abivax Obefazimod Appointment Mark Stenhouse
PRESS RELEASE published on 11/13/2024 at 22:01, 1 year 5 months ago Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax appoints Mark Stenhouse, former Prometheus COO, as Board Observer & Advisor, bringing extensive biopharma experience to support clinical therapeutics development Abivax Mark Stenhouse Prometheus Board Observer Clinical Therapeutics
BRIEF published on 10/11/2024 at 18:05, 1 year 6 months ago ABIVAX terminates its liquidity contract Liquidity Contract Biotechnology Termination Trading Abivax
BRIEF published on 10/11/2024 at 18:05, 1 year 6 months ago ABIVAX: Number of Shares and Voting Rights as of September 30, 2024 Euronext Paris Share Capital Voting Rights AMF Abivax
PRESS RELEASE published on 10/11/2024 at 18:00, 1 year 6 months ago ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement. Abivax terminates liquidity contract with TSAF SA, releasing details of assets in the account and transactions. Company focuses on developing therapies for chronic inflammatory diseases Liquidity Contract Termination Abivax Therapeutics Immune Response
Published on 05/02/2026 at 21:00, 1 day 1 hour ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 20 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 21 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 22 hours ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 22 hours ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/03/2026 at 20:10, 2 hours 17 minutes ago A Decade of Learning Across Borders: PKU's South-South Institute Turns 10
Published on 05/03/2026 at 04:45, 17 hours 42 minutes ago GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 1 day 6 hours ago Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 2 days 3 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/30/2026 at 20:00, 3 days 2 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 3 days 3 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 3 days 3 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 3 days 4 hours ago Minutes of the Combined General Meeting held on April 30, 2026
